Revisiting the management of chronic ITP; a randomized controlled clinical trial.

Platelets
Ghada E M AbdallahAhmad F Thabet

Abstract

The balance between therapy effectiveness and economic efficiency in chronic immune thrombocytopenia (ITP) becomes more confusing. This single-center open label randomized controlled trial evaluates the effectiveness and safety of hydroxychloroquine in chronic ITP patients against other affordable second-line treatments. It is registered under number (NCT03229746) at Clinical Trials.gov. 120 patients were recruited and randomly allocated to three arms of hydroxychloroquine, vincristine, and azathioprine equally. Platelet counts of more than 100 × 109/L were interpreted as complete response (CR), while response (R) was determined as platelet counts ranging from 30 × 109/L to less than 100 × 109/L with the doubling of the pretreatment platelet count. Overall response (OR) was defined to include both CR and R. Patients were monitored every 6 weeks for a total of 24 weeks. The population baseline characteristics regarding age, sex, duration of the disease, baseline platelets count, and presence of antinuclear antibodies ANA or antiplatelet antibodies were similar among tested groups. There was a significant difference in the overall response between hydroxychloroquine (80.6%) and azathioprine (55.9%) (p-value <0.05). This differenc...Continue Reading

References

Oct 1, 1995·Clinical and Experimental Immunology·R B LandewéB A Dijkmans
Jan 1, 1997·Journal of Clinical Gastroenterology·B B MenteşE Tatlicioğlu
Sep 15, 1998·Acta Paediatrica. Supplement·J Andersson
Feb 14, 2002·The Journal of Behavioral Health Services & Research·John S LyonsPeter Tracy
Mar 22, 2003·British Journal of Haematology·Emmanuelle BourgeoisPierre Fenaux
Mar 31, 2009·Seminars in Hematology·Douglas B CinesRoberto Stasi
Feb 18, 2011·Blood·Cindy NeunertUNKNOWN American Society of Hematology
Jul 17, 2014·JAMA : the Journal of the American Medical Association·Jacques-Eric GottenbergXavier Mariette
May 16, 2015·European Journal of Haematology·Jérôme StirnemannOlivier Fain
Oct 1, 2015·La Revue de médecine interne·S AudiaB Bonnotte
Dec 4, 2016·Hematology·Rachael F Grace, Cindy Neunert
Feb 18, 2017·Journal of Clinical Medicine·Anne ZuffereyJohn W Semple
Apr 19, 2017·Blood·Michele P Lambert, Terry B Gernsheimer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Related Papers

Archives of Ophthalmology
M Frenkel
Retinal Cases & Brief Reports
Michael F Marmor
The British Journal of Ophthalmology
A G Lee
© 2021 Meta ULC. All rights reserved